Abbott Laboratories (ABT) is -1.12% away from 50-day simple Moving Average despite all headwinds

On Monday, Abbott Laboratories (NYSE: ABT) was 0.01% up from the session before settling in for the closing price of $132.02. A 52-week range for ABT has been $99.71 – $141.23.

It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 29.98%. When this article was written, the company’s average yearly earnings per share was at 10.49%. With a float of $1.73 billion, this company’s outstanding shares have now reached $1.74 billion.

The extent of productivity of a business whose workforce counts for 114000 workers is very important to gauge. In terms of profitability, gross margin is 55.89%, operating margin of 16.97%, and the pretax margin is 17.37%.

Abbott Laboratories (ABT) Insider and Institutional Ownership

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Abbott Laboratories stocks. The insider ownership of Abbott Laboratories is 0.67%, while institutional ownership is 79.91%. The most recent insider transaction that took place on Apr 30 ’25, was worth 337,116. In this transaction Director of this company sold 2,600 shares at a rate of $129.66, taking the stock ownership to the 34,058 shares. Before that another transaction happened on Apr 30 ’25, when Company’s Director proposed sale 2,600 for $129.66, making the entire transaction worth $337,116.

Abbott Laboratories (ABT) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around 10.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.36% during the next five years compared to 29.98% growth over the previous five years of trading.

Abbott Laboratories (NYSE: ABT) Trading Performance Indicators

You can see what Abbott Laboratories (ABT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.27. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.42. Likewise, its price to free cash flow for the trailing twelve months is 34.51.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 7.71, a number that is poised to hit 1.25 in the next quarter and is forecasted to reach 5.69 in one year’s time.

Technical Analysis of Abbott Laboratories (ABT)

The latest stats from [Abbott Laboratories, ABT] show that its last 5-days average volume of 4.76 million was inferior to 6.72 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 21.41%.

During the past 100 days, Abbott Laboratories’s (ABT) raw stochastic average was set at 55.68%, which indicates a significant increase from 9.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.63 in the past 14 days, which was lower than the 2.78 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $133.52, while its 200-day Moving Average is $124.88. Now, the first resistance to watch is $132.84. This is followed by the second major resistance level at $133.66. The third major resistance level sits at $134.22. If the price goes on to break the first support level at $131.46, it is likely to go to the next support level at $130.90. The third support level lies at $130.08 if the price breaches the second support level.

Abbott Laboratories (NYSE: ABT) Key Stats

There are 1,739,836K outstanding shares of the company, which has a market capitalization of 229.71 billion. As of now, sales total 41,950 M while income totals 13,402 M. Its latest quarter income was 10,358 M while its last quarter net income were 1,325 M.